{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Joseph DB"],"funding":["National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","National Cancer Institute","NCI NIH HHS","American Urological Association Foundation"],"pagination":["427-441"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8930464"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["256(4)"],"pubmed_abstract":["Benign prostatic hyperplasia (BPH) is a progressive expansion of peri-urethral prostate tissue common in aging men. Patients with enlarged prostates are treated with 5-alpha reductase inhibitors (5ARIs) to shrink prostate volume by blocking the conversion of testosterone to dihydrotestosterone (DHT). A reduction in DHT levels can elicit atrophy and apoptosis of prostate secretory luminal cells, which results in a favorable clinical response characterized by improved lower urinary tract symptoms. However, the histologic response to 5ARI treatment is often heterogeneous across prostate acini and lower urinary tract symptoms can persist to require surgical intervention. We used two spatial profiling approaches to characterize gene expression changes across histologically normal and atrophied "],"journal":["The Journal of pathology"],"pubmed_title":["5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia."],"pmcid":["PMC8930464"],"funding_grant_id":["P30CA016056","R01DK115477","659333","R01 DK115477","P30CA142543","P30 CA016056","U54 DK104310","P30 CA142543","U54DK104310"],"pubmed_authors":["Malewska A","Mohler JL","Henry GH","Hutchinson RC","Joseph DB","Reese JC","Roehrborn CG","Mauck RJ","Strand DW","Gahan JC"],"additional_accession":[]},"is_claimable":false,"name":"5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.","description":"Benign prostatic hyperplasia (BPH) is a progressive expansion of peri-urethral prostate tissue common in aging men. Patients with enlarged prostates are treated with 5-alpha reductase inhibitors (5ARIs) to shrink prostate volume by blocking the conversion of testosterone to dihydrotestosterone (DHT). A reduction in DHT levels can elicit atrophy and apoptosis of prostate secretory luminal cells, which results in a favorable clinical response characterized by improved lower urinary tract symptoms. However, the histologic response to 5ARI treatment is often heterogeneous across prostate acini and lower urinary tract symptoms can persist to require surgical intervention. We used two spatial profiling approaches to characterize gene expression changes across histologically normal and atrophied ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-21T22:36:01.884Z","creation":"2025-04-05T18:48:43.135Z"},"accession":"S-EPMC8930464","cross_references":{"pubmed":["34928497"],"doi":["10.1002/path.5857"]}}